onr:"swepub:oai:DiVA.org:uu-90342"
Search: onr:"swepub:oai:DiVA.org:uu-90342" > Immunization of col...
- 1 of 1
- Previous record
- Next record
- To hitlist
Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response
-
- Ullenhag, Gustav (author)
- Uppsala universitet,Enheten för onkologi
-
- Frödin, Jan-Erik (author)
- Karolinska Institutet
- Mosolits, Szilvia (author)
- show more...
- Bonnet, Marie-Claude (author)
- Moingeon, Philippe (author)
- show less...
- (creator_code:org_t)
- 2003
- 2003
- English.
- In: Clinical Cancer Research. - 1078-0432 .- 1557-3265. ; 9:7, s. 2447-2456
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- PURPOSE: Colorectal carcinoma cells express the tumor-associated antigen epithelial cellular adhesion molecule (Ep-CAM)/KSA. Passive immunotherapy with monoclonal antibodies using this antigen has shown promising results. Ep-CAM might also be a target for active specific immunotherapy. Expression of the tumor antigen in a viral vector may facilitate appropriate antigen presentation. The feasibility of an Ep-CAM/KSA-specific therapeutic vaccination was investigated in cancer patients.EXPERIMENTAL DESIGN: The full-length Ep-CAM gene was inserted into the avipox virus ALVAC (ALVAC-KSA). Twelve radically operated colorectal carcinoma patients without evidence of remaining macroscopic disease (stages I, II, and III) entered the study. The first 6 patients were immunized with three injections of ALVAC-KSA (10(7.09) CCID(50) per immunization) alone in weeks 0, 3, and 6. The subsequent 6 patients received the same schedule of ALVAC-KSA together with the adjuvant cytokine granulocyte macrophage colony-stimulating factor (GM-CSF; 75 micro g/day for 4 consecutive days).RESULTS: The adverse reactions to the vaccinations were mild except for local skin reactions. In the ALVAC-KSA group a weak T-cell response was induced in 2 of 6 patients. In the ALVAC-KSA/GM-CSF group a marked IFN-gamma response (enzyme-linked immunospot) was induced in 5 of 6 patients. The T-cell response appeared late, 1 month after the last immunization, with a peak at 4-5 months after immunization. No IgG antibodies against Ep-CAM were detected. Before vaccination the majority of patients had a type 1 T-cell response (IFN-gamma) against the vector, which was noted in healthy donors as well. All of the patients developed high titers of IgG antibodies against the vector, and the T-cell response was vigorously boosted.CONCLUSIONS: ALVAC-KSA, in combination with low dose local administration of GM-CSF may induce a strong, IFN-gamma T-cell response (type 1). ALVAC-KSA seems to be an interesting candidate as a cancer vaccine for future clinical development.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Clinical Cancer Research (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Ullenhag, Gustav
- Frödin, Jan-Erik
- Mosolits, Szilvi ...
- Kiaii, Shahryar
- Hassan, Moustaph ...
- Bonnet, Marie-Cl ...
- show more...
- Moingeon, Philip ...
- Mellstedt, Håkan
- Rabbani, Hodjata ...
- show less...
- Articles in the publication
- Clinical Cancer ...
- By the university
- Uppsala University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
